Journal List > Korean J Physiol Pharmacol > v.28(1) > 1516085710

TOOLS
Yang, Huang, Wang, Nie, Huang, and Li: Wogonin attenuates vascular remodeling by inhibiting smooth muscle cell proliferation and migration in hypertensive rat
Original Article

Korean J. Physiol. Pharmacol. 2024;28(1):39-48.

Published online: 1 January 2024

DOI: https://doi.org/10.4196/kjpp.2024.28.1.39

Wogonin attenuates vascular remodeling by inhibiting smooth muscle cell proliferation and migration in hypertensive rat

Yang Yang1, Shan Huang1, Jun Wang1, Xiao Nie2, Ling Huang3, *, Tianfa Li1, *

1Department of Cardiovasology, The First Affiliated Hospital, Hainan Medical University, Haikou 570100, China

2Hainan Eye Hospital and Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Haikou 570311, China

3Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China

*Correspondence Ling Huang, E-mail: 15740427@qq.com, Tianfa Li, E-mail: litianfadoctor@hotmail.com

Contributed by:

Author contributions: Y.Y. were the main designers of this study. Y.Y., S.H., J.W., T.L., and X.N. performed the experiments and analyzed the data. L.H., T.L., and Y.Y. drafted the manuscript. All authors read and approved the final manuscript.

Received 16 August 2023       Revised 23 November 2023       Accepted 24 November 2023

Copyright © Korean J Physiol Pharmacol

(open-access):

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Wogonin, extracted from the roots of Scutellaria baicalensis Georgi, has been shown to suppress collagen deposition in spontaneously hypertensive rats (SHRs). This study was performed to investigate the role and mechanism of wogonin underlying vascular remodeling in SHRs. After injection of SHRs with 40 mg/kg of wogonin, blood pressure in rats was measured once a week. Masson's trichrome staining was conducted to observe the changes in aortas and mesenteric arteries. Vascular smooth muscle cells (VSMCs) isolated from rat thoracic aortas were treated with Angiotensin II (Ang II; 100 nM) in the presence or absence of varying concentrations of wogonin. The viability and proliferation of VSMCs were examined using Cell Counting Kit-8 assay and 5-ethynyl-2’-deoxyuridine assay, respectively. The migration of VSMCs was examined using wound healing assay and transwell assay. We found that wogonin administration alleviated hypertension, increased lumen diameter, and reduced the thickness of the arterial media in SHRs. Ang II treatment enhanced the viability of VSMCs, which was inhibited by wogonin in a concentration-dependent manner. Wogonin reversed Ang II-induced increases in the viability, proliferation, and migration of VSMCs. Moreover, wogonin inhibited Ang II-induced activation of mitogen-activated protein kinase (MAPK) signaling in VSMCs. Overall, wogonin repressed the proliferative and migratory capacity of VSMCs by regulating the MAPK signaling pathway, thereby attenuating vascular remodeling in hypertensive rats, indicating that wogonin might be a therapeutic agent for the treatment of vascular diseases.

Keywords: Angiotensins, Flavonoids, Hypertension, Vascular remodeling

INTRODUCTION

Hypertension is the main cause of cardiovascular diseases and affects more than 25% of the global population [1]. During vascular injury, vascular smooth muscle cells (VSMCs) switch from a quiescent "contractile" phenotype to a highly migratory and proliferative "synthetic" phenotype [2]. Increasing studies have demonstrated that abnormal proliferation and migration of VSMCs play key roles in the pathogenesis and development of cardiovascular disorders, such as diabetic vascular complications, transplantation arteriopathy, atherosclerosis, and hypertension [3,4]. Vascular remodeling is considered to be protective in the short term but harmful in the long term, and these pathological effects of vascular remodeling are related to increased risks of cardiovascular diseases [5]. Therefore, reversing hypertension-related vascular remodeling is of great importance for the prevention of hypertension progression.
Hypertension-induced vascular remodeling can be mediated by activation of the renin-angiotensin system [6]. It has been demonstrated that the renin-angiotensin system plays an important role during vascular remodeling. As a multi-functional hormone, angiotensin II (Ang II) is crucial for vascular homoeostasis via angiotensin II receptor type 1 (AT1R) or AT2R [7]. Studies have shown that Ang II has a high level in the serum of spontaneously hypertensive rats (SHRs) [8,9]. Ang II regulates vascular function, including contraction, growth, and fibrosis, and contributes to increased vascular permeability by initiating inflammatory responses [10]. It is also a powerful vasoconstrictive factor that induces the phenotypic conversion of SMCs and participates in vascular remodeling [10,11]. Therefore, Ang II has been commonly used to establish the in vitro models of SAHs [12,13].
Scutellaria baicalensis Georgi has a long history in the treatment of inflammation and hypertension in Eastern Asian countries [14]. Wogonin is one of the flavonoids extracted from the dried root of Scutellaria baicalensis Georgi and possesses multiple pharmacological and biological effects including neuroprotective, anti-inflammation, antioxidation, anti-angiogenesis, and anticancer activities [14-17]. Previous reports demonstrated that wogonin treatment inhibits serum-induced rabbit VSMC proliferation [18], TNF-alpha-induced human aortic SMC (HASMC) migration [19], and lipotoxicity-induced apoptosis of VSMCs [20]. In addition, the anti-angiogenesis role of wogonin has also been found in tumors and interleukin-6-induced human umbilical vein endothelial cells [21,22]. Moreover, wogonin represses collagen deposition in cardiac fibroblasts of Wistar-Kyoto rats (WKYs) and SHRs [23], and also exerts vasodilatory effect in male Wistar rats [24]. A recent study shows that wogonin attenuates cisplatin-induced cardiotoxicity in animal models [25]. However, the role of wogonin in vascular remodeling remains unclear.
The mitogen-activated protein kinase (MAPK) signaling is an important pathway consisting of three family members, p38 MAPK, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) [26]. It has been reported that activation of MAPK signaling promotes hypoxic pulmonary vascular remodeling via stimulation of the migration and proliferation as well as reduction of the apoptosis of pulmonary artery SMCs [27]. Wogonin has been shown to suppress TNF-alpha-induced migration of HASMCs in vitro by suppressing MAPK signaling [19]. Therefore, we hypothesized that wogonin also regulates MAPK pathway in Ang II-induced VSMCs.
The purpose of the present study was to investigate the role and mechanism of wogonin in SHRs. We hypothesized that wogonin may alleviate vascular remodeling by suppressing VSMC proliferation and migration by regulating MAPK pathway, which may provide a potential therapeutic agent to ameliorate vascular remodeling.

METHODS

Animal procedures

Nine-week-old male SHRs and WKYs were purchased from BioLasco Co., Ltd. All rats had free access to drinking water and normal rat chow in a temperature-controlled (24°C ± 2°C) room with a 12-h dark/light cycle. SHRs with systolic blood pressure (SBP) higher than 150 mmHg were selected for this study. Animal experiment was performed in accordance with the principles of the Guide for the Care and Use of Laboratory Animals (National Institutes of Health [NIH], 8th edition, 2011). In addition, we ensure that the manuscript report conforms to the ARRIVE guidelines for animal experiment reports. All animal experiments were approved by the Ethical Review System for Laboratory Animal Welfare of the Wuhan Myhalic Biotechnology Co., Ltd (approval number: 202205041). After acclimation for seven days, WKYs or SHRs were intravenously injected with wogonin (purity ≥ 99.0%; Yunnan Yunyao Laboratory Company Limited) at a dose of 40 mg/kg or equal amount of normal saline every other day for three weeks. The dose of wogonin was selected according to a previous study [28]. Three weeks later, all rats were euthanized with 200 mg/kg pentobarbital sodium (Scrbio) and the aortas and mesenteric arteries (MAs) were collected for further use.

Measurement of blood pressure

After treatment, animal models were placed in a warm room, and the SBP, diastolic blood pressure (DBP), and mean arterial pressure (MAP) of the tail artery were measured once a week by the tail-cuff method using a noninvasive computerized tail-cuff system (NIBP, ADInstruments).

Masson's trichrome staining

The aortas and MAs isolated from WKYs and SHRs were fixed with formalin, embedded in paraffin and sliced into 2-mm sections. The sections were deparaffinized in xylene and then rehydrated in alcohol gradient. Masson's trichrome dye was used to stain the sections and the images were captured under a microscope. Evaluation of vascular remodeling was performed according to the media cross-sectional area, lumen diameter, media thickness, media thicknesses/lumen diameter ratio, and outer diameter.

Cell culture and treatment

Primary VSMCs were isolated from rat thoracic aortas as previously performed [29]. The obtained VSMCs were maintained in Dulbecco's modified Eagle's medium (DMEM, YT8231; YITA Bio) containing 10% fetal bovine serum (FBS, 76294-180; AVANTOR), 1% penicillin-streptomycin (15140-122; Gibco) at 37°C in the presence of 5% CO2 and 95% O2. VSMCs were treated with Ang II (100 nM; Sigma) alone for 6, 12, and 24 h, coincubated with Ang II (100 nM) and wogonin (0.1, 1, 3, 10, and 20 μM) for 24 h, or co-incubated with Ang II (100 nM) and wogonin (10 μM) for 24 h.

Cell Counting Kit-8 (CCK-8) assay

VSMCs (7 × 103 cells/well) were plated in 96well plates and were treated with Ang II or/and wogonin for 24 h. Next, 10 μl of CCK-8 solution (PUFFE Biotechnology Co., Ltd.) was added to each well of the plates to incubate the cells for 4 h. A microplate reader was used to detect the absorbance of each well at 450 nm.

5-ethynyl-2’-deoxyuridine (EdU) assay

EdU assay was performed to detect the proliferation of VSMCs following the product manuals. Cells were fixed with 4% paraformaldehyde and then incubated with EdU working solution for 2 h. 4’,6-diamidino2-phenylindole (D8200-10; Solarbio) was used to stain the cells for 15 min in the dark. Cell proliferation was evaluated by calculating the percentage of EdU-positive cells using a fluorescence microscope (Nikon).

Transwell assay

Cells cultured serumfree DMEM medium were placed in the upper chamber and DMEM supplemented with 10% FBS was placed in its lower chamber. After incubation for 24 h at 37°C, a cotton swab was used to remove the cells on the upper surface of the membrane, and the cells that had migrated to the lower surface were fixed and stained with 0.1% crystal violet. The number of migrated cells was measured by counting under a light microscope.

Wound healing assay

Cells in 6well plates were cultured at 37°C for 24 h and allowed to reach 80% confluence. The cell monolayer was wounded by scratching using a sterile micropipette tip. After incubation in serum-free DMEM for 24 h, an inverted microscope was used, and wound healing percentages were analyzed with ImageJ software (NIH).

Western blot analysis

Total proteins were extracted by lysing VSMCs in RIPA lysis buffer (R0020-100; Solarbio), followed by quantification of the protein content using a BCA protein quantification kit (E112-01; Vazyme Biotechnology Co., Ltd.). Afterwards, equal amounts of protein samples (50 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred on a PVDF membrane (Millipore). After blocking with 5% skimmed milk, all membranes were probed with primary antibodies, including anti-phospho (p)-p38 (ab4822, 1:1,000), anti-p38 (ab170099, 1:5,000), anti-p-JNK (ab76572, 1:5,000), anti-JNK (ab208035, 1:2,000), anti-p-ERK (ab201015, 1:1,000), anti-ERK (ab184699, 1:10,000), anti-cyclin-dependent kinase4 (CDK4, ab199728, 1:1,000), anti-Cyclin D1 (ab16663, 1:200), anti-matrix metalloproteinase2 (MMP2, ab92536, 1:1,000), anti-matrix metalloproteinase9 (MMP9, ab76003, 1:1,000), and anti-GAPDH (ab181603, 1:1,000) at 4°C overnight. The membranes were rinsed with Tris Buffered Saline with Tween three times and incubated with anti-rabbit secondary antibody (ab96899, 1:10,000) at room temperature for 1 h. Protein bands were visualized with an ECL kit and quantified with ImageJ software (NIH). GAPDH acted as loading control.

Statistical analysis

All data were analyzed using SPSS 20.0 software (IBM Corp.) and are displayed as the mean ± SD. For multiple group comparisons, one-way analysis of variance together with Tukey’s post-hoc test was used. Each experiment was performed at least in triplicate. p < 0.05 was considered statistically significant.

RESULTS

Wogonin attenuates vascular remodeling in hypertensive rats

High blood pressure indices, including SBP, DBP, and MAP were measured in WKYs and SHRs. We observed that SBP, DBP, and MAP were increased in SHRs compared to WKYs. Wogonin administration reduced the SBP, DBP, and MAP of SHRs two weeks after injection, and exerted no significant effect on blood pressure during the first week (Fig. 1A–C). Masson’s staining was performed to evaluate vascular remodeling in the aortas and MAs of WKYs and SHRs (Fig. 1D–G). Compared to WKYs, significant increases in the thickness of media and the media thickness/lumen diameter ratio were found in the aortas and MAs of SHRs. However, wogonin administration significantly reversed increased thickness of media and media thickness/lumen diameter ratio in SHRs. A notable reduction in lumen diameter was found in the MAs of SHRs, which was restored after the treatment of wogonin. Additionally, the images of the aorta showed less blue color levels in the wogonin treatment group compared to the control group, both in WKYs and SHRs, demonstrating the inhibitory effect of wogonin on collagen deposition in the aortas and MAs of hypertensive rats.

Wogonin suppresses the viability of Ang II-treated VSMCs

Ang II-stimulated VSMCs have been widely used to establish the in vitro models of SAHs [12,13,30]. To investigate the effect of wogonin on cell viability, VSMCs were treated with 100 nM Ang II for 6, 12, and 24 h, respectively. The concentrations of Ang II were used according to previous studies [31,32]. The CCK-8 assay results showed that the viability of VSMCs was enhanced by Ang II treatment in a time-dependent manner, compared to the control group (Fig. 2A). As previously studies reported [19], wogonin (Fig. 2B) under 20 μM of concentration had no toxicity on VSMCs. We found that wogonin inhibited the viability of Ang II-treated VSMCs in a concentration-dependent manner, while the viability was slightly increased when the concentration of wogonin was 20 μM (Fig. 2C). Therefore, we chose 10 μM of wogonin for the subsequent investigations.

Administration of wogonin inhibits the proliferation and migration of VSMCs

CCK-8 assay was performed to detect the effect of wogonin on VSMC viability, and the results revealed that wogonin treatment reversed Ang II-mediated increase in the viability of VSMCs (Fig. 3A). Consistent with the CCK-8 results, wogonin treatment notably reduced the percentage of EdU positive cells in Ang II-treated VSMCs, demonstrating that wogonin inhibited Ang II-induced cell proliferation (Fig. 3B, C). Wound healing assay and transwell assay were conducted to assess the impact of wogonin on VSMC migration. In wound healing assay, Ang II stimulation notably enhanced wound closure rate in VSMCs, and this effect was reversed by wogonin (Fig. 3D, F). In transwell assay, wogonin treatment significantly reduced the number of migrated cells in Ang II-treated VSMCs (Fig. 3E, G), indicating that wogonin inhibited the migration and invasion of VSMCs.

Wogonin inhibits Ang II-induced activation of MAPK signaling in VSMCs

A previous study has shown that wogonin protects against endotoxin-induced acute lung injury by reducing the phosphorylation of MAPKs [14]. Therefore, we investigated whether wogonin also regulates the MAPK signaling in Ang II-induced VSMCs. The results of Western blot showed that Ang II significantly enhanced the phosphorylation levels of ERK, JNK, and p38 in VSMCs, which were reduced by treatment with wogonin (Fig. 4A–D). Therefore, wogonin administration leads to suppression of MAPK signaling pathway in Ang II-induced VSMCs. To further verify the anti-proliferation and anti-migration effects of wogonin, we examined the expression of proliferation- and migration-related markers. The results of western blot revealed that the protein levels of CDK4, Cyclin D1, matrix metalloproteinases MMP2, and MMP9 were upregulated by Ang II in VSMCs, and wogonin treatment reversed the effect of Ang II on these markers (Fig. 4E–I).

DISCUSSION

Vascular remodeling is related to hypertension that is an important predisposing factor for cardiovascular diseases [29]. Wogonin is a flavonoid extracted from the root of Scutellaria baicalensis Georgi and has high potential to treat cardiovascular diseases. Our study revealed the role of wogonin in vascular remodeling. We found that wogonin ameliorated vascular remodeling in SHRs by inhibiting VSMC proliferation and migration via suppression of the MAPK signaling pathway.
Almost all organs and tissues can be affected by vascular remodeling in patients with hypertension. Vascular remodeling is characterized by reduced vascular compliance, enhanced media thickness, and intimal injury [33]. Due to the extensive use of SHRs in the evaluation of the effect of drugs on hypertensive vascular remodeling [34], this animal model was used to investigate the role of wogonin in our study. We found that wogonin (40 mg/kg) decreased SBP, DBP, and MAP in SHRs. In addition, significant improvements were observed in the vascular wall of aortas and MAs, as manifested by reduced media thickness and increased lumen diameter, suggesting the beneficial benefits of wogonin in improving vascular remodeling in SHRs.
Phenotypic transition of VSMCs is a key determinant of vascular homeostasis. Unlike skeletal or cardiac muscle cells, VSMCs switches from contractile phenotype to a highly migratory and proliferative synthetic phenotype in response to injured stimuli [35]. Increasing evidence has shown that hyperproliferation and abnormal migration of VSMCs promote vascular remodeling and facilitate the process of various vascular diseases [36-38]. Previous studies have confirmed that Ang II plays a key role in the proliferation and migration of VSMCs and is widely used for the exploration of the mechanisms of cardiovascular diseases [39]. In our current study, Ang II at a dose of 100 nM was used to treat VSMCs for 6, 12, and 24 h. We found that Ang II significantly enhanced the viability of VSMCs in a time-dependent manner. Notably, wogonin treatment inhibited Ang II-promoted viability of VSMCs. Moreover, the effects of Ang II on the proliferation and migration of VSMCs were significantly reversed by wogonin administration. These findings are consistent with the wogonin’s effects on serum-induced rabbit VSMC and TNF-alpha-induced HASMC [18,19] as well as in a serious of human cancers (e.g., hepatocellular carcinoma, gastric cancer, melanoma, and renal cell carcinoma) [40-43].
The MAPK signaling pathway has been known to modulate cell proliferation, apoptosis, transformation, and differentiation [44]. Previous reports have revealed that the MAPK signaling stimulates the proliferation and migration whereas decreases the apoptosis of SMCs to contribute to vascular remodeling. For example, TCONS_00034812 depletion promotes the proliferation but suppresses the apoptosis of SMCs by activating the MAPK signaling [45]. Srolo Bzhtang suppresses vascular remodeling and pulmonary arterial pressure by inhibiting MAPK signaling in rat models [46]. Additionally, the suppressive effect of wogonin on MAPK signaling has been verified in acute lung injury [14], TNF-alpha-induced HASMCs [19], intervertebral disc degeneration [47], and rheumatoid arthritis [48]. Consistent with previous studies, our study showed that the Ang II-induced increased phosphorylation levels of ERK, JNK, and p38 MAPK were inhibited by treatment with wogonin, suggesting that wogonin blocked the MAPK signaling to suppress the proliferation and migration of VSMCs.
In conclusion, our current investigation demonstrated that wogonin attenuated vascular remodeling in SHRs by restraining Ang II-induced proliferation and migration of VSMCs via inhibition of the MAPK signaling pathway, suggesting that wogonin might be a novel therapeutic agent for the treatment of vascular diseases. It has been demonstrated that after intragastric administration of 5 mg/kg wogonin, little wogonin is detected in the plasma of rat models. It suggests that intravenous administration might be the clinical administration method of wogonin [49]. Although wogonin offers a wide margin of safety [50], the extract dosage of wogonin applied in clinical patients deserves careful confirmation in future studies.

ACKNOWLEDGEMENTS

The authors appreciate all the participants providing supports for this study.

Notes

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. 2005; Global burden of hypertension: analysis of worldwide data. Lancet. 365:217–223. DOI: 10.1016/S0140-6736(05)17741-1. PMID: 15652604.
2. Xu MM, Deng HY, Li HH. 2019; MicroRNA-27a regulates angiotensin II-induced vascular smooth muscle cell proliferation and migration by targeting α-smooth muscle-actin in vitro. Biochem Biophys Res Commun. 509:973–977. DOI: 10.1016/j.bbrc.2019.01.047. PMID: 30654940.
3. Rizzoni D, Agabiti Rosei E. 2006; Small artery remodeling in hypertension and diabetes. Curr Hypertens Rep. 8:90–95. DOI: 10.1007/s11906-006-0046-3. PMID: 16600165.
4. Wang D, Uhrin P, Mocan A, Waltenberger B, Breuss JM, Tewari D, Mihaly-Bison J, Huminiecki Ł, Starzyński RR, Tzvetkov NT, Horbańczuk J, Atanasov AG. 2018; Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways. Biotechnol Adv. 36:1586–1607. DOI: 10.1016/j.biotechadv.2018.04.006. PMID: 29684502.
5. Schiffrin EL. 2012; Vascular remodeling in hypertension: mechanisms and treatment. Hypertension. 59:367–374. DOI: 10.1161/HYPERTENSIONAHA.111.187021. PMID: 22203749.
6. Mendoza-Torres E, Oyarzún A, Mondaca-Ruff D, Azocar A, Castro PF, Jalil JE, Chiong M, Lavandero S, Ocaranza MP. 2015; ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis. 9:217–237. DOI: 10.1177/1753944715597623. PMID: 26275770.
7. Touyz RM. 2005; Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol. 90:449–455. DOI: 10.1113/expphysiol.2005.030080. PMID: 15890798.
8. Dai B, Wang ZZ, Zhang H, Han MX, Zhang GX, Chen JW. 2020; Antihypertensive properties of a traditional Chinese medicine GAO-ZI-YAO in elderly spontaneous hypertensive rats. Biomed Pharmacother. 131:110739. DOI: 10.1016/j.biopha.2020.110739. PMID: 32932045.
9. Liu L, Shi Q, Liu X, Li Y, Li X. 2022; Attenuation of myocardial fibrosis using molecular hydrogen by inhibiting the TGF-β signaling pathway in spontaneous hypertensive rats. Am J Hypertens. 35:156–163. DOI: 10.1093/ajh/hpab159. PMID: 34618887.
10. Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. 2014; Angiotensin II and vascular injury. Curr Hypertens Rep. 16:431. DOI: 10.1007/s11906-014-0431-2. PMID: 24760441.
11. Mehta PK, Griendling KK. 2007; Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 292:C82–C97. DOI: 10.1152/ajpcell.00287.2006. PMID: 16870827.
12. Shen A, Wu M, Ali F, Guo Z, Fang Y, Zhou Y, Zhang S, Zhang W, Wen Y, Yu M, Peng J, Chen K. 2023; Based on network pharmacology, gastrodin attenuates hypertension-induced vascular smooth muscle cell proliferation and PI3K/AKT pathway activation. Sci Rep. 13:12140. DOI: 10.1038/s41598-023-39202-6. PMID: 37495624. PMCID: PMC10372005. PMID: 6e734266f8a6410589aa43e8f8341890.
13. Ye C, Geng Z, Zhang LL, Zheng F, Zhou YB, Zhu GQ, Xiong XQ. 2022; Chronic infusion of ELABELA alleviates vascular remodeling in spontaneously hypertensive rats via anti-inflammatory, anti-oxidative and anti-proliferative effects. Acta Pharmacol Sin. 43:2573–2584. DOI: 10.1038/s41401-022-00875-w. PMID: 35260820. PMCID: PMC9525578.
14. Wei CY, Sun HL, Yang ML, Yang CP, Chen LY, Li YC, Lee CY, Kuan YH. 2017; Protective effect of wogonin on endotoxin-induced acute lung injury via reduction of p38 MAPK and JNK phosphorylation. Environ Toxicol. 32:397–403. DOI: 10.1002/tox.22243. PMID: 26892447.
15. Baumann S, Fas SC, Giaisi M, Müller WW, Merling A, Gülow K, Edler L, Krammer PH, Li-Weber M. 2008; Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCγ1- and Ca2+-dependent apoptosis. Blood. 111:2354–2363. DOI: 10.1182/blood-2007-06-096198. PMID: 18070986.
16. Lee H, Kim YO, Kim H, Kim SY, Noh HS, Kang SS, Cho GJ, Choi WS, Suk K. 2003; Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia. FASEB J. 17:1943–1944. DOI: 10.1096/fj.03-0057fje. PMID: 12897065.
17. Chi YS, Cheon BS, Kim HP. 2001; Effect of wogonin, a plant flavone from Scutellaria radix, on the suppression of cyclooxygenase-2 and the induction of inducible nitric oxide synthase in lipopolysaccharide-treated RAW 264.7 cells. Biochem Pharmacol. 61:1195–1203. DOI: 10.1016/S0006-2952(01)00597-4. PMID: 11322923.
18. Huang HC, Wang HR, Hsieh LM. 1994; Antiproliferative effect of baicalein, a flavonoid from a Chinese herb, on vascular smooth muscle cell. Eur J Pharmacol. 251:91–93. DOI: 10.1016/0014-2999(94)90447-2. PMID: 8137874.
19. Lee SO, Jeong YJ, Yu MH, Lee JW, Hwangbo MH, Kim CH, Lee IS. 2006; Wogonin suppresses TNF-alpha-induced MMP-9 expression by blocking the NF-kappaB activation via MAPK signaling pathways in human aortic smooth muscle cells. Biochem Biophys Res Commun. 351:118–125. DOI: 10.1016/j.bbrc.2006.10.006. PMID: 17052690.
20. Liu YM, Wang X, Nawaz A, Kong ZH, Hong Y, Wang CH, Zhang JJ. 2011; Wogonin ameliorates lipotoxicity-induced apoptosis of cultured vascular smooth muscle cells via interfering with DAG-PKC pathway. Acta Pharmacol Sin. 32:1475–1482. DOI: 10.1038/aps.2011.120. PMID: 21986573. PMCID: PMC4010212.
21. Wang SJ, Zhao JK, Ren S, Sun WW, Zhang WJ, Zhang JN. 2019; Wogonin affects proliferation and the energy metabolism of SGC-7901 and A549 cells. Exp Ther Med. 17:911–918. DOI: 10.3892/etm.2018.7023. PMID: 30651880. PMCID: PMC6307470.
22. Lin CM, Chang H, Chen YH, Wu IH, Chiu JH. 2006; Wogonin inhibits IL-6-induced angiogenesis via down-regulation of VEGF and VEGFR-1, not VEGFR-2. Planta Med. 72:1305–1310. DOI: 10.1055/s-2006-951692. PMID: 17024605.
23. Kong EK, Huang Y, Sanderson JE, Chan KB, Yu S, Yu CM. 2010; Baicalein and Wogonin inhibit collagen deposition in SHR and WKY cardiac fibroblast cultures. BMB Rep. 43:297–303. DOI: 10.5483/BMBRep.2010.43.4.297. PMID: 20423617.
24. Qu JT, Zhang DX, Liu F, Mao HP, Ma YK, Yang Y, Li CX, Qiu LZ, Geng X, Zhang JM, Gao XM, Chen L, Wang H. 2015; Vasodilatory effect of wogonin on the rat aorta and its mechanism study. Biol Pharm Bull. 38:1873–1878. DOI: 10.1248/bpb.b15-00444. PMID: 26632179.
25. Xu J, Zhang B, Chu Z, Jiang F, Han J. 2021; Wogonin alleviates cisplatin-induced cardiotoxicity in mice via inhibiting Gasdermin D-mediated pyroptosis. J Cardiovasc Pharmacol. 78:597–603. DOI: 10.1097/FJC.0000000000001085. PMID: 34651602. PMCID: PMC8492184.
26. Decean HP, Brie IC, Tatomir CB, Perde-Schrepler M, Fischer-Fodor E, Virag P. 2018; Targeting MAPK (p38, ERK, JNK) and inflammatory CK (GDF-15, GM-CSF) in UVB-activated human skin cells with Vitis vinifera seed extract. J Environ Pathol Toxicol Oncol. 37:261–272. DOI: 10.1615/JEnvironPatholToxicolOncol.2018027009. PMID: 30317975.
27. Cao X, Fang X, Guo M, Li X, He Y, Xie M, Xu Y, Liu X. 2021; TRB3 mediates vascular remodeling by activating the MAPK signaling pathway in hypoxic pulmonary hypertension. Respir Res. 22:312. DOI: 10.1186/s12931-021-01908-4. PMID: 34906150. PMCID: PMC8670293. PMID: cd5268d388f74d458e3317039598cf1f.
28. Talbi A, Zhao D, Liu Q, Li J, Fan A, Yang W, Han X, Chen X. 2014; Pharmacokinetics, tissue distribution, excretion and plasma protein binding studies of wogonin in rats. Molecules. 19:5538–5549. DOI: 10.3390/molecules19055538. PMID: 24786691. PMCID: PMC6270787. PMID: 68472b83616a4e2092e0e4593dcb45d7.
29. Tian L, Cai D, Zhuang D, Wang W, Wang X, Bian X, Xu R, Wu G. 2020; miR-96-5p regulates proliferation, migration, and apoptosis of vascular smooth muscle cell induced by angiotensin II via targeting NFAT5. J Vasc Res. 57:86–96. DOI: 10.1159/000505457. PMID: 32045906.
30. Yang H, Liu J, Chen X, Li G. 2022; Angptl2 gene knockdown is critical for abolishing angiotensin II-induced vascular smooth muscle cell proliferation and migration. Biochem Cell Biol. 100:59–67. DOI: 10.1139/bcb-2021-0191. PMID: 34860608.
31. Zhang Y, Qian X, Sun X, Lin C, Jing Y, Yao Y, Ma Z, Kuai M, Lu Y, Kong X, Chen Q, Wu X, Zhao X, Li Y, Bian H. 2018; Liuwei Dihuang, a traditional Chinese medicinal formula, inhibits proliferation and migration of vascular smooth muscle cells via modulation of estrogen receptors. Int J Mol Med. 42:31–40. DOI: 10.3892/ijmm.2018.3622. PMID: 29693116. PMCID: PMC5979928.
32. Kang G, Lee YR, Joo HK, Park MS, Kim CS, Choi S, Jeon BH. 2015; Trichostatin A modulates angiotensin II-induced vasoconstriction and blood pressure via inhibition of p66shc activation. Korean J Physiol Pharmacol. 19:467–472. DOI: 10.4196/kjpp.2015.19.5.467. PMID: 26330760. PMCID: PMC4553407.
33. Zhong X, Ma Z, Su Y, Li Z, Liao Y, Pan X, Zang L, Zhou S. 2020; Flavin adenine dinucleotide ameliorates hypertensive vascular remodeling via activating short chain acyl-CoA dehydrogenase. Life Sci. 258:118156. DOI: 10.1016/j.lfs.2020.118156. PMID: 32735886.
34. Gao Y, Ren C, Li X, Yu W, Li S, Li H, Wang Y, Li D, Ren M, Ji X. 2021; Ischemic conditioning ameliorated hypertension and vascular remodeling of spontaneously hypertensive rat via inflammatory regulation. Aging Dis. 12:116–131. DOI: 10.14336/AD.2020.0320. PMID: 33532132. PMCID: PMC7801289.
35. Lu QB, Wan MY, Wang PY, Zhang CX, Xu DY, Liao X, Sun HJ. 2018; Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFκB/mTOR/P70S6K signaling cascade. Redox Biol. 14:656–668. DOI: 10.1016/j.redox.2017.11.012. PMID: 29175753. PMCID: PMC5716955.
36. He L, Zhou Q, Huang Z, Xu J, Zhou H, Lv D, Lu L, Huang S, Tang M, Zhong J, Chen JX, Luo X, Li L, Chen L. 2019; PINK1/Parkin-mediated mitophagy promotes apelin-13-induced vascular smooth muscle cell proliferation by AMPKα and exacerbates atherosclerotic lesions. J Cell Physiol. 234:8668–8682. Erratum. DOI: 10.1002/jcp.27527. PMID: 30456860.
37. Huynh DTN, Heo KS. 2021; Role of mitochondrial dynamics and mitophagy of vascular smooth muscle cell proliferation and migration in progression of atherosclerosis. Arch Pharm Res. 44:1051–1061. DOI: 10.1007/s12272-021-01360-4. PMID: 34743301.
38. Shi N, Chen SY. 2016; Smooth muscle cell differentiation: model systems, regulatory mechanisms, and vascular diseases. J Cell Physiol. 231:777–787. DOI: 10.1002/jcp.25208. PMID: 26425843.
39. Zhao XS, Zheng B, Wen Y, Sun Y, Wen JK, Zhang XH. 2019; Salvianolic acid B inhibits Ang II-induced VSMC proliferation in vitro and intimal hyperplasia in vivo by downregulating miR-146a expression. Phytomedicine. 58:152754. DOI: 10.1016/j.phymed.2018.11.014. PMID: 31009837.
40. Hong M, Cheng H, Song L, Wang W, Wang Q, Xu D, Xing W. 2018; Wogonin suppresses the activity of matrix metalloproteinase-9 and inhibits migration and invasion in human hepatocellular carcinoma. Molecules. 23:384. DOI: 10.3390/molecules23020384. PMID: 29439451. PMCID: PMC6017513. PMID: 124e68c7eb1445d5a3770879f7558bd1.
41. Wang XH, Wei YF, Cheng H. 2016; Effects of Wogonin on apoptosis, invasion, migration and Wnt/β-catenin signaling pathway of gastric cancer cells SGC7901. Zhong Yao Cai. 39:1372–1376. Chinese. PMID: 30156810.
42. Li L, Ji Y, Zhang L, Cai H, Ji Z, Gu L, Yang S. 2021; Wogonin inhibits the growth of HT144 melanoma via regulating hedgehog signaling-mediated inflammation and glycolysis. Int Immunopharmacol. 101:108222. DOI: 10.1016/j.intimp.2021.108222. PMID: 34688155.
43. Wang Y, Chen S, Sun S, Liu G, Chen L, Xia Y, Cui J, Wang W, Jiang X, Zhang L, Zhu Y, Zou Y, Shi B. 2020; Wogonin induces apoptosis and reverses sunitinib resistance of renal cell carcinoma cells via inhibiting CDK4-RB pathway. Front Pharmacol. 11:1152. DOI: 10.3389/fphar.2020.01152. PMID: 32792963. PMCID: PMC7394056. PMID: 667947bfe28642028a7128837ca2bc1b.
44. Sun Y, Liu WZ, Liu T, Feng X, Yang N, Zhou HF. 2015; Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 35:600–604. DOI: 10.3109/10799893.2015.1030412. PMID: 26096166.
45. Liu Y, Sun Z, Zhu J, Xiao B, Dong J, Li X. 2018; LncRNA-TCONS_00034812 in cell proliferation and apoptosis of pulmonary artery smooth muscle cells and its mechanism. J Cell Physiol. 233:4801–4814. DOI: 10.1002/jcp.26279. PMID: 29150946.
46. Chen T, Su S, Yang Z, Zhang D, Li Z, Lu D. 2022; Srolo Bzhtang reduces inflammation and vascular remodeling via suppression of the MAPK/NF-κB signaling pathway in rats with pulmonary arterial hypertension. J Ethnopharmacol. 297:115572. DOI: 10.1016/j.jep.2022.115572. PMID: 35872290.
47. Fang W, Zhou X, Wang J, Xu L, Zhou L, Yu W, Tao Y, Zhu J, Hu B, Liang C, Li F, Hua J, Chen Q. 2018; Wogonin mitigates intervertebral disc degeneration through the Nrf2/ARE and MAPK signaling pathways. Int Immunopharmacol. 65:539–549. DOI: 10.1016/j.intimp.2018.10.024. PMID: 30412851.
48. Huang Y, Guo L, Chitti R, eeharsha N Sr, Mishra A, Gubbiyappa SK, Singh Y. 2020; Wogonin ameliorate complete Freund's adjuvant induced rheumatoid arthritis via targeting NF-κB/MAPK signaling pathway. Biofactors. 46:283–291. DOI: 10.1002/biof.1585. PMID: 31721330.
49. Du Y, Chen XY, Yang HY, Zhong DF. 2002; Determination of wogonin in rat plasma by liquid chromatography-tandem mass spectrometry. Yao Xue Xue Bao. 37:362–366. Chinese. PMID: 12579842.
50. Peng J, Qi Q, You Q, Hu R, Liu W, Feng F, Wang G, Guo Q. 2009; Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs. J Ethnopharmacol. 124:257–262. DOI: 10.1016/j.jep.2009.04.031. PMID: 19397969.

Fig. 1

Wogonin alleviates vascular remodeling in SHRs.

The rats were intravenously injected with wogonin (40 mg/kg) or NS every other day for 3 weeks. (A–C) The SBP, DBP, and MAP were measured in each conscious rat once a week within 3 weeks. (D) Representative images of aortas and MAs in WKYs and SHRs by Masson’s trichrome staining. Scale bar = 100 μm (aorta), Scale bar = 200 μm (MA). (E–G) Quantification of media thickness, lumen diameter, and the ratio of media thickness/lumen diameter in aortas and MAs of SHRs and WKYs based on Masson’s staining results. N = 8 in each group. Measurement data are expressed as the mean ± SD. SHRs, spontaneously hypertensive rats; WKYs, Wistar-Kyoto rats; NS, normal saline; MAs, mesenteric arteries; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure. *p < 0.05, **p < 0.01, ***p < 0.001.
kjpp-28-1-39-f1.tif
Fig. 2

Effects of wogonin on the viability of VSMCs treated with Ang II.

(A) CCK-8 kit was used to measure the viability of VSMCs that were treated with Ang II (100 nM) for 6, 12, and 24 h. (B) Chemical structure of wogonin. (C) VSMCs were treated with Ang II (100 nM) alone or in combination with 0, 0.1, 1, 3, 10, or 20 μM of wogonin for 24 h. Cell viability was examined using CCK-8 assay. N = 3. Measurement data are expressed as the mean ± SD. VSMCs, vascular smooth muscle cells; Ang II, angiotensin II; CCK-8, Cell Counting Kit-8; OD, optical density. **p < 0.01.
kjpp-28-1-39-f2.tif
Fig. 3

Wogonin administration suppresses the proliferation and migration of Ang II-treated VSMCs.

VSMCs were treated with Ang II (100 nM) in the presence or absence of wogonin (10 μM) or NS for 24 h. (A) The viability of VSMCs in the groups of Control, Ang II, Ang II + NS, and Ang II + Wogonin was assessed using CCK8 assay. (B) EdU assay was performed for cell proliferation assessment. Scale bar = 100 μM. (C) Bar graph showing the percentage of EdU-positive cells. (D) Representative images of migrated cells from wound healing assay. (E) Representative images of migrated cells from transwell assay. Scale bar = 200 μM. (F) Bar graph showing the wound closure rate. (G) Quantification of migrated cells from transwell assay. Measurement data are expressed as the mean ± SD. VSMCs, vascular smooth muscle cells; Ang II, angiotensin II; CCK-8, Cell Counting Kit-8; EdU, 5-ethynyl-2’-deoxyuridine; NS, normal saline. **p < 0.01, ***p < 0.001.
kjpp-28-1-39-f3.tif
Fig. 4

Effects of wogonin on the phosphorylation of MAPKs.

VSMCs were treated with Ang II (100 nM) in the presence or absence of wogonin (10 μM) or NS for 24 h. (A) The levels of the key proteins in the MAPK signaling pathway in Control, Ang II, Ang II + NS, and Ang II + Wogonin groups were examined using Western blot analysis. (B–D) The ratio of p-ERK/ERK, p-JNK/JNK, and p-p38/p38 was calculated. N = 3. (E) The protein levels of CDK4, Cyclin D1, MMP2, and MMP9 in the Control, Ang II, Ang II + NS, and Ang II + Wogonin groups were examined using Western blot analysis. (F–I) The protein levels of CDK4, Cyclin D1, MMP2, and MMP9 were quantified. N = 3. Measurement data are expressed as the mean ± SD. MAPK, mitogen-activated protein kinase; VSMCs, vascular smooth muscle cells; Ang II, angiotensin II; NS, normal saline; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; CDK4, cyclin-dependent kinase4; MMP2, matrix metalloproteinase2; MMP9, matrix metalloproteinase9. **p < 0.01.
kjpp-28-1-39-f4.tif
TOOLS
Similar articles